methylphenidate has been researched along with Cancer of Prostate in 3 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether methylphenidate can alleviate fatigue, as measured by the Functional Assessment of Cancer Therapy: Fatigue subscale, in men with prostate cancer (PCa) treated with a luteinizing hormone-releasing hormone (LHRH) for a minimum of 6 months, and to assess changes in global fatigue and quality of life (QoL) as measured by the Bruera Global Fatigue Severity Scale (BFS) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), respectively." | 9.20 | Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. ( Alibhai, SM; Bhatt, JR; Chahin, R; Fleshner, NE; Hersey, KM; Richard, PO, 2015) |
| "This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients." | 9.14 | Methylphenidate for fatigue in ambulatory men with prostate cancer. ( Arauz, G; Breitbart, W; Morris, M; Nelson, C; O'Shea, N; Rosenfeld, B; Roth, AJ; Scher, H; Slovin, S, 2010) |
| "To investigate whether methylphenidate can alleviate fatigue, as measured by the Functional Assessment of Cancer Therapy: Fatigue subscale, in men with prostate cancer (PCa) treated with a luteinizing hormone-releasing hormone (LHRH) for a minimum of 6 months, and to assess changes in global fatigue and quality of life (QoL) as measured by the Bruera Global Fatigue Severity Scale (BFS) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), respectively." | 5.20 | Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. ( Alibhai, SM; Bhatt, JR; Chahin, R; Fleshner, NE; Hersey, KM; Richard, PO, 2015) |
| "This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients." | 5.14 | Methylphenidate for fatigue in ambulatory men with prostate cancer. ( Arauz, G; Breitbart, W; Morris, M; Nelson, C; O'Shea, N; Rosenfeld, B; Roth, AJ; Scher, H; Slovin, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richard, PO | 1 |
| Fleshner, NE | 1 |
| Bhatt, JR | 1 |
| Hersey, KM | 1 |
| Chahin, R | 1 |
| Alibhai, SM | 1 |
| Roth, AJ | 1 |
| Nelson, C | 1 |
| Rosenfeld, B | 1 |
| Scher, H | 1 |
| Slovin, S | 1 |
| Morris, M | 1 |
| O'Shea, N | 1 |
| Arauz, G | 1 |
| Breitbart, W | 1 |
| Vigano, A | 1 |
| Watanabe, S | 1 |
| Bruera, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomized, Double-blind, Placebo Controlled Trial of Methylphenidate Hydrochloride for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy[NCT00593853] | Phase 2 | 33 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to Slow Accrual) | ||
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for methylphenidate and Cancer of Prostate
| Article | Year |
|---|---|
Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
Topics: Androgen Antagonists; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Humans; Male; | 2015 |
Methylphenidate for fatigue in ambulatory men with prostate cancer.
Topics: Aged; Ambulatory Care; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; Fatig | 2010 |
1 other study available for methylphenidate and Cancer of Prostate
| Article | Year |
|---|---|
Methylphenidate for the management of somatization in terminal cancer patients.
Topics: Humans; Male; Methylphenidate; Middle Aged; Prostatic Neoplasms; Somatoform Disorders; Terminal Care | 1995 |